EMA Authorised: Adynovi (rurioctocog alfa pegol) — Baxalta Innovations GmbH

View source ↗

Summary

The European Medicines Agency authorized Adynovi (rurioctocog alfa pegol) from Baxalta Innovations GmbH for use in Hemophilia A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• ADYNOVI (recombinant antihemophilic factor VIII Fc fusion protein)

Snippet

Status: Authorised. Therapeutic area: Hemophilia A. MAH: Baxalta Innovations GmbH. Decision date: 13/07/2023